Introduction
The cell cycle of mammalian cells is regulated by a very complex machinery, of which cyclins and cyclin dependent protein kinases (CDKs) play essential roles (reviewed in Pines, 1995; Nigg, 1995) . Multiple cyclin-CDK complexes undergo changes in the kinase and cyclin moieties which are believed to drive the cell cycle from one stage to another. An important element of this cyclin regulated cell cycle is the rapid induction of cell cycle phase speci®c cyclin expression and facile destruction of these cyclins as cells progress through the next phase of the cell cycle. In mammalian cells, the D-type cyclins (reviewed in Sherr, 1995) , in association with the cyclin-dependent kinases cdk4 or cdk6, regulate the progression of the G 1 phase of the cell cycle mainly by participating in the phosphorylation of the retinoblastoma gene product pRb (reviewed in Weinberg, 1995) . As a result of phosphorylation of pRb, free E2F, of which ®ve family members have been identi®ed to date (Sardet et al., 1995; , is released from complexes containing E2F and the hypophosphorylated form of pRb. The`free' E2F, which is present as a heterodimer with its binding partner DP-1 or DP-2 (Wu et al., 1995) , is the active transcription factor that promotes the transcription of E2F target genes such as dihydrofolate reductase (DHFR) (Blake and Azizkhan, 1989) , thymidylate synthase (TS) (Johnson, 1994) and other genes necessary for entry into and progression through the S phase of the cell cycle (Adams and Kaelin, 1995; DeGregori et al., 1995) . Cyclin A and the B-type cyclins (cyclins B1 and B2), in complexes with CDK2 and CDC2, respectively, are essential for S-phase progression and for G 2 /M phase transition (reviewed in Pines and Hunter, 1992) .
The mammalian cell cycle is negatively regulated mostly through action of cyclin dependent kinase inhibitors (CDKIs) (reviewed in Sherr and Roberts, 1995) , many of which have been identi®ed recently. The most important CDKIs include p21 Waf1 , a universal CDK inhibitor (Xiong et al., 1993) whose expression is regulated by the p53 tumor suppressor protein (elDeiry et al., 1993) ; p16 INK4 , a speci®c inhibitor of cyclin D/CDK4/6 that is identi®ed recently as a tumor suppressor gene product (Marx, 1994); and p27 Kip1 , which is involved in cellular response to cAMP and other antiproliferative signals Kato et al., 1994) . p21
Waf1 plays a pivotal role in p53-mediated cell cycle arrest upon stress such as DNA damage (Brugarolas et al., 1995; Macleod et al., 1995) . The ras oncogenes (including H-, K-and N-ras), which are activated by point mutations, are implicated in carcinogenesis (reviewed in Barbacid, 1990; Rodenhuis, 1992) . About 30% of all human tumors are associated with ras mutations and up to 95% of human pancreatic cancers contain K-ras mutations (Mangues and Pellicer, 1992; Rodenhuis, 1992) . Ras proteins play central roles in receptor-mediated signal transduction pathways that control cell proliferation and dierentiation (Khosravi-Far and Der, 1994; Medema and Bos, 1993) . Increasing evidence supports the notion that one of the ultimate targets of the ras signaling pathway is the nuclear transcription machinery including the transcription factors c-Jun and Ets, whose activity has been shown to be regulated by oncogenic ras (Westwick et al., 1994; Yang et al., 1996) . Therefore, ras plays an essential role in transducing external signals (such as growth factors or other mitogens) to the nucleus.
Earlier work demonstrated that microinjection of Ras protein into quiescent cells induces DNA synthesis (Stacey and Kung, 1984) , suggesting that the ras signaling pathway is directly linked to the G 1 /S transition of the cell cycle. The link between ras and the cell cycle has been strengthened by more recent reports showing that activated ras induces cyclin D 1 in NIH3T3 cells (Winston et al., 1996; Filmus et al., 1994) and that the raf kinase, a putative downstream target of ras, interacts with and regulates the activity of cdc25 (Galaktionov et al., 1995) , a phosphatase involved in regulation of cdc2, an essential G 2 /M kinase. However, the direct roles of ras in regulation of the very complex cell cycle machinery is yet to be elucidated. The current study was undertaken to study the eect of activated ras on the cell cycle and on the expression of cell cycle related genes and to understand the functional roles of ras in relationship to cell cycle control. Ultimately, the information obtained in this study should help to identify the molecular target(s) of activated ras and provide guidance for chemotherapy of tumors containing activated ras.
Results

Inducible expression of an activated K-ras in MCF-7 cells
In order to minimize the likelihood of artifacts caused by clonal variation (which is reduced, if not eliminated, by use of an inducible expression system), a common problem associated with stable transfections using noninducible expression vectors, MCF-7 cells were cloned and cells from a single clone (#2) (which harbors normal ras genes as determined by sequencing analysis (data not shown)) were used to obtain stable transfectants expressing inducible human activated Kras under the control of a tetracycline-responsive promoter. After selection with G418, one clone designated as M2TK4 was obtained which contained the activated K-ras gene, as shown by PCR using a primer speci®c for the CMV promoter and another speci®c for exon 1 of the K-ras gene (data not shown). This PCR step was necessary because the plasmid in which the K-ras gene resides does not have a selectable marker. Western blotting analysis using a K-ras speci®c antibody revealed that expression of the activated K-ras was induced by Tet withdrawal (lane 1, Figure 1) as compared to the level of expression in the presence of Tet (lane 2). The latter most likely represented the endogenous level of K-ras expression rather than the`leakiness' of the system as the level of K-ras expression in M2TK4 cells in the presence of Tet was comparable to that in non-transfected MCF-7 cells (data not shown). These data indicate that K-ras expression can be eectively regulated (turned on or o) by Tet.
Eect of activated K-ras expression on cell growth and the cell cycle distribution Although induction of K-ras expression in M2TK4 cells had no eect on cell morphology (data not shown), induction of activated K-ras did lead to accelerated cell growth as shown in Figure 2a . The doubling times of M2TK4 cells grown in media containing 10% Fetal Bovine Serum (FBS) ( Figure  2a , left panel) and in the presence or absence of Tet were 29 and 24 h, respectively. When these cells were grown in a low serum (0.1%) medium, there was a clear acceleration of cell growth when activated K-ras was induced by Tet withdrawal (Figure 2a , right panel), although the overall cell growth was much slower under these conditions compared to normal growth conditions (i.e. 10% serum). The eect of activated K-ras on cell cycle (i.e. % of cells in S phase) was measured by use of pulse-chase labeling with BrdU followed by¯ow cytometric analysis. As shown in Figure 2b , induction of activated K-ras in M2TK4 cells led to an increased percentage of cells in S phase (from 26% to 35%). These data indicated that activated K-ras can accelerate both cell growth and cell cycle (i.e. G 1 -S transition). Careful examination of Figure  2b indicated that there appeared to be a sub-fraction of cells (indicated by the arrow) which were in G 1 phase but BrdU-positive. This sub-population of cells was not evident in M2TK4 cells growing in the presence of Tet. One possible explanation for this observation is that the BrdU-positive G 1 cells were those that were in very late S-phase and were about to enter G 2 /M, that had progressed through G 2 /M and then returned to G 1 phase of the cell cycle. These data raise the possibility that in addition to acceleration of G 1 /S transition, activated K-ras may play a role in acceleration of G 2 /M transition as well.
Eect of activated K-ras on expression of certain Sphase enzymes
Since induction of activated K-ras in M2TK4 cells stimulated cell growth and accelerated the cell cycle (Figure 2 ), Western blotting analysis was performed to determine whether the increased growth rate and accelerated cell cycle are accompanied by increased levels of enzymes such as dihydrofolate reductase and thymidylate synthase which are essential for DNA replication and cell growth. When activated K-ras was induced by tetracycline withdrawal in cells grown in 10% FBS, there was a slight increase in the level of
Figure 1 Inducible expression of activated K-ras in MCF-7 cells transfected with activated K-ras cDNA. Cells from a clone (M2TK4) of a single clone-derived MCF-7 cells stably transfected with the activated K-ras cDNA contained in a tetracycline inducible expression system (see the Materials and methods section for details), maintained in RPMI 1640 medium containing 1 mg/ml of Tet, were grown to mid-log phase in the presence of Tet and split (by trypsinization) into two parts. Cells from one part were grown in the absence of Tet while those from the other part were grown in the presence of 1 mg/ml of Tet. After a 48 h incubation, cells (mid-log phase) were collected and proteins from the total cellular extracts were subjected to polyacrylamide gel electrophoresis in the presence of SDS (SDS ± PAGE), followed by Western blotting using an anti-K-ras2 antibody (see the Materials and methods section for details). Arrow indicates the position of the K-ras protein. The ®gure is a representative of three dierent experiments Figure 2 Eect of activated K-ras on cell growth and the cell cycle. (a) Cell growth measurement. M2TK4 cells (mid-log phase) that have been maintained in RPMI 1640 medium containing or lacking Tet (1 mg/ml) were plated in a series of 96-well plates, which contain media supplemented with either 10% (at 2000 cells per well) or 0.1% FBS (at 5000 cells per well), with or without Tet added, respectively. The cells were incubated at 378C for 24 h to allow cell attachment. From this point (as time 0 h), and at the indicated time intervals, cell growth was measured by a standard sulforodamine B binding assay as described previously (Fan et al., 1997) . The results shown are ratios of cell growth at various time points to that at time 0 h and are means+standard deviations from eight experiments. (b) Cell cycle analysis. M2TK4 cells, maintained in media containing Tet (1 mg/ml), were plated in media (supplemented with 10% serum) containing or lacking Tet (1 mg/ml). After growth for 72 h, the cells were labeled with 10 mM Bromodeoxyuridine (BrdU) for 3 h and then collected by trypsinization. After ®xation with 70% ethanol, followed by denaturation with 2N HCl, labeling with anti-BrdU-FITC conjugates, and staining with 5 mg/ml propidium iodide, the cells were subjected tō ow cytometric analysis (see the Materials and methods section for further details). Relative FITC¯uorescence (vertical axis) was plotted as a function of DNA contents (PI¯uorescence, horizontal axis). Percent of cells in S phase was calculated. The background FITC¯uorescence was accessed from a control experiment (left, b) in which wild type MCF-7 cells were processed in the same manner except that the cells were not labeled with BrdU. The results represent one of two independent experiments TS protein (compare lanes 1 and 2, Figure 3b) ; the level of DHFR expression was not changed (lanes 1 and 2, Figure 3a) . When M2TK4 cells growing in the presence or absence of Tet were exposed to a low serum (0.1% FBS) medium for 24 h, however, there was a signi®cant increase in the levels of both DHFR and TS expression upon Tet withdrawal (compare lanes 3 and 4 in Figure 3a and b). It was reported previously (Graham et al., 1986) that MCF-7 cells may contain high levels of endogenous (normal) ras, which can be activated by serum factors presumably through growth factor receptor pathways. Therefore, when cells are grown in media containing a high concentration (10%) of serum, the eect of the activated K-ras transgene (i.e. the transfected activated K-ras) may not be apparent unless the cells were subjected to treatment with media containing a low concentration (0.1%) of serum, a condition in which the eect of endogenous ras is greatly reduced if not eliminated. For these reasons, in the subsequent studies (see below), the eect of activated K-ras will be studied both in cells grown in regular media (containing 10% serum) and in cells that have been subjected to an additional serum deprivation treatment (with media containing 0.1% serum).
Dierential regulation of the D-type cyclins by the activated K-ras
Since D-type cyclins, which are composed of three members (D1, D2, D3), are known to play essential roles in G 1 to S transition in the cell cycle (Sherr, 1995) , it was of interest to determine whether activated K-ras mediates this cell cycle acceleration through regulation of any or all of these D-type cyclins. This was accomplished by Western blotting analysis, using antibodies speci®c for each member of the D-cyclin family, of protein extracts from M2TK4 cells grown in the presence or absence of Tet. As shown in Figure 4 , when activated K-ras was induced by Tet withdrawal and cells were grown in medium containing 10% serum, there was a slight increase in the level of cyclin D3 expression compared to cells grown in the presence of Tet (lanes 1 and 2, Figure  4a) . However, the level of cyclin D3 expression was signi®cantly upregulated upon induction of the activated K-ras by Tet withdrawal when cells were subjected to a 24 h serum deprivation with medium containing 0.1% serum before being collected for protein extraction. The up-regulation of cyclin D3 by activated K-ras correlated with cyclin D3-associated kinase activity in an experiment in which an anticyclin D3 antibody was used to immunoprecipitate the kinase(s) complexed with cyclin D3 and Histone H1 was used as the substrate (data not shown). The eect of activated K-ras on the levels of cyclin D1 and cyclin D2 expression was analysed in a similar manner. As shown in Figure 4b and c, no obvious dierence in the level of either cyclin D1 or cyclin D2 expression was observed when cells were grown either in the presence or in the absence of Tet, with or without the serum deprivation step described above. These data show that induction of activated K-ras upregulated only one member of the D-type cyclin family ± cyclin D3 ± while having no eect on cyclins D1 and D2. Eect of activated K-ras on expression of two S-phase enzymes. M2TK4 cells (mid-log), maintained in the presence of Tet, were grown to mid-log phase (a 48 h incubation) in media containing or lacking Tet (2 mg/ml), using multiple tissue culturē asks. Cells from one half of these¯asks (growing in the presence or absence of Tet) were subjected to an additional 24 h serum deprivation by incubating cells with media containing 0.1% FBS, with or without Tet added, respectively. Cells were collected by trypsinization and proteins from the total cellular extract were subjected to SDS ± PAGE followed by Western blotting with a polyclonal anti-DHFR antibody ( 
Induction of activated K-ras leads to upregulation of the E2F family of transcription factors
Since the E2F family of transcription factors play a pivotal role in progression through the G 1 phase of the cell cycle and entry into S phase (Johnson et al., 1993) , it was of interest to determine whether activated K-ras mediates cell cycle acceleration through regulation of any or all of the E2F family of transcription factors, of which ®ve members have been identi®ed to date. Of these ®ve members, E2F-1, 2, and 3 preferentially bind to pRb while E2F-4 and E2F-5 preferentially bind the pRb-related proteins p107 and p130, respectively (Beijersbergen et al., 1994; Hijmans et al., 1995) . Western blotting analysis, using an antibody speci®c for E2F-1 showed that induction of activated K-ras by Tet withdrawal resulted in a signi®cant increase in the level of E2F-1 expression ( Figure 5a , compare lanes 1 and 2). This induction of E2F-1 by the activated K-ras appeared to be more profound when cells growing in the presence or absence of Tet were subjected to a 24 h serum deprivation (as described above) ( Figure 5a , compare lanes 3 and 4). Although serum starvation led to a decrease in overall E2F-1 expression in cells exposed or not exposed to Tet, signi®cant expression of E2F-1 was evident when activated K-ras was induced in serum-starved cells while E2F-1 expression was almost non-detectable in these cells under non-induced conditions. Eect of induction of activated K-ras on expression of E2F-4 and E2F-5, other two distinct members of the E2F family of transcription factors, was studied in the same manner using antibodies speci®c for E2F-4 and E2F-5, respectively. As shown in Figure 5b and c, induction of activated K-ras by Tet withdrawal resulted in a signi®cant increase in the levels of E2F-4 and E2F-5 either with or without serum deprivation. Interestingly, serum deprivation did not appear to have much eect on the overall expression of these E2F species as compared to E2F-1. These data clearly indicate that induction of activated K-ras leads to upregulation of all major forms of the E2F transcription factors.
Induction of the E2F transcription factors by activated K-ras is consistent with increased E2F transcriptional activity
The transcriptional activity of members of the E2F family of transcription factors is regulated by multiple cell cycle-related events, such as increased expression (transcriptionally or post-transcriptionally) (Slansky et al., 1993) , phosphorylation (for E2F-1, 2 and 3) by cyclin A/cdk2 complexes (Xu et al., 1994) and complex formation with pRb or pRb-related proteins p107 and p130. Therefore, increased expression of the E2F protein may not necessarily lead to increased transcriptional activity. The E2F transcriptional activity was measured by transient transfection of M2TK4 cells with a plasmid containing the CAT reporter gene driven by a E2F-responsive promoter. As shown in Figure 6 , Eect of activated K-ras on expression of members of the E2F family of transcription factors. M2TK4 cells were grown to mid-log phase, in the presence or absence of Tet, with or without a serum deprivation step, as described in the legend for Figure 3 . Cells were collected by trypsinization and proteins from the total cellular extract were subjected to SDS ± PAGE followed by Western blotting with speci®c monoclonal antibody against E2F-1 (a), E2F-4 (b) or E2F-5 (c). Positions of E2F-1, -2 and -5 are indicated by arrows. The ®gure represents one of at least three dierent experiments Figure 6 Eect of activated K-ras on E2F transcriptional activity. M2TK4 cells were grown to ca. 40 ± 50% con¯uency, in the presence or absence of Tet, in multiple tissue culture dishes. After 24 h growth, cells were co-transfected, using lipofection, with pE2FCAT (which contains an E2F responsive minimal TK promoter driving the expression of the CAT reporter gene) and pSV2luc (which contains the luciferase gene driven by the SV40 promoter). After an additional 72 h growth, cells from one half of these dishes (growing in the presence or absence of Tet) were subjected to 24 h serum deprivation by incubating cells with media containing 0.1% FBS, with or without Tet added, respectively. Cells were collected and assayed for both CAT and luciferase activities. The results represent the means+s.e. of relative CAT activities (after correction for transfection eciency using luciferase activities) from three experiments. For details, see the Materials and methods section when activated K-ras was induced by Tet withdrawal, there was a fourfold increase in overall E2F transcriptional activity (as indicated by relative CAT activity after correction for transfection eciency using a separate reporter plasmid containing the luciferase gene) as compared to the result obtained from cells grown in the presence of Tet. Similar results were obtained when transfected cells growing in the presence or absence of Tet were subjected to serum deprivation (0.1% serum, 24 h) before being collected for the CAT assay. These results indicated that induction of the activated K-ras leads to increased E2F transcriptional activity.
Up-regulation of cyclins A and E by activated K-ras
Although cyclin A, initially characterized as a`mitotic cyclin ' (Walker and Maller, 1991) , is considered to function as an S-phase cyclin (Zindy et al., 1992; Pagano et al., 1992) , recent work (Carbonaro-Hall et al., 1993; Rosenberg et al., 1995) suggests that cyclin A activity may also be essential for G 1 /S progression. Therefore, the eect of activated K-ras on expression of both cyclin A and cyclin E (a G 1 cyclin; Ohtsubo et al., 1995) , was studied. Western blotting analysis using a speci®c antibody against cyclin A (Figure 7a ) indicated that induction of activated K-ras by Tet withdrawal in M2TK4 cells led to a signi®cant increase in cyclin A protein when cells were grown in media containing 10% serum (with or without Tet) (lanes 1 and 2). However, when cells growing in the presence or absence of Tet were subjected to a 24 h serum deprivation, cyclin A expression became undetectable and induction of K-ras failed to upregulate cyclin A. Cyclin A, like other cyclins, forms active complexes with its corresponding CDKs (i.e. CKD2) to drive cell cycle progression (Devoto et al., 1992) . To determine whether upregulation of cyclin A by activated K-ras plays a role in cell cycle regulation, cyclin A-associated kinase activity was determined by measuring the ability of the cyclin A immunoprecipitate from total cellular extract to phosphorylate Histone H1 protein. As shown in Figure 7b , when activated K-ras was induced by Tet withdrawal and cells were grown in medium containing 10% serum, there was a signi®cant increase in cyclin Aassociated kinase activity compared to cells grown in the presence of Tet (lanes 1 and 2).
The eect of activated K-ras on expression of cyclin E, a G 1 cyclin, was studied in a similar manner. As shown in Figure 7c , activated K-ras also induces cyclin E in cells grown with regular medium (lanes 1 and 2) but not in cells which were serum starved (lanes 3 and 4). These data suggest that activated K-ras regulates both cyclin A and cyclin E, and most likely by a dierent mechanism from that for cyclin D3 in that upregulation of cyclin A and cyclin E by activated K-ras may require the presence of certain serum factors while up-regulation of cyclin D3 does not.
Regulation of cyclin A by activated K-ras occurs at the transcriptional level
Transient transfection of M2TK4 cells with a plasmid containing the cyclin A promoter which drives the expression of the reporter gene luciferase was performed to measure the eect of induction of activated K-ras on the promter activity of cyclin A. As shown in Figure 8 , induction of activated K-ras by Tet withdrawal leads to a signi®cant increase in the promoter activity of cyclin A (as indicated by relative luciferase activity after correction for transfection eciency using a separate reporter plasmid containing the CAT gene). Similar results were obtained when transfected cells growing in the presence or absence of Tet were subjected to serum deprivation (0.1% serum, 24 h) before being collected for the luciferase assay. These results indicate that the activated K-ras regulates cyclin A expression at the transcriptional level.
Induction of activated K-ras leads to down-regulation of p27 Kip1
While the E2F family of transcription factors are known to be positive regulators of the cell cycle, inhibitors of cyclins and cyclin dependent kinases such as p27
Kip1 are negative regulators of the cell cycle. The earlier observations that overexpression of activated ras, in some special cases, resulted in cell cycle arrest (Pan et al., 1994; Hirakawa and Ruley, 1988) prompted us to examine whether activated K-ras, shown to regulate several positive regulators of the cell cycle, can Regulation of cyclins A and E by activated K-ras. (a and c) M2TK4 cells were grown to mid-log phase, in the presence or absence of Tet, with or without a serum deprivation step, as described in the legend for Figure 3 . Cells were collected by trypsinization and proteins from the total cellular extract were subjected to SDS ± PAGE followed by Western blotting with speci®c monoclonal antibody against cyclin A (a) or cyclin E (c). Positions of cyclins A and E are indicated by arrows. The ®gure represents one of three similar experiments. (b) Histone H1 kinase assay. M2TK4 cells (mid-log), maintained in the presence of Tet, were grown to mid-log phase (a 48 h incubation) in media containing or lacking Tet (2 mg/ml). Cells were collected by trypsinization and the total cellular extract (containing 200 mg protein) were subjected to immunoprecipitation with anti-cyclin A antibody-agarose conjugates followed by Histone H1 assay as described in the Materials and methods section. The position of the phosphorylated Histone H1 was indicated by the arrow. This represents one of two similar experiments regulate some of the`negative' cell cycle regulators. Therefore, the eect of activated K-ras expression on p27
Kip1 was examined by Western blotting using speci®c antibodies against this protein. As shown in Figure 9 , induction of activated K-ras by Tet withdrawal resulted in a signi®cant decrease in the level of p27 Kip1 expression (compare lanes 1 and 2). This eect (i.e. repression of p27
Kip1 expression by activated K-ras) was retained in cells growing in the presence or absence of Tet followed by a 24 h serum deprivation (compare lanes 3 and 4). These data suggest that induction of activated K-ras decreases the expression of p27 Kip1 , which could contribute, at least in part, to an accelerated cell cycle.
Induction of activated K-ras leads to upregulation of p53 and its eectors p21 waf1 and Gadd 45
A previous study by Hicks et al. (1991) showed that overexpression of an activated ras gene in the rat embryo ®broblast cell line REF52 results in growth arrest which may be released by expression of dominant negative mutants of p53, indicating that wild type p53 activity may be essential for ras-mediated growth arrest. Therefore, it was of interest to test whether activated K-ras directly regulates the expression of the tumor suppressor protein p53. Western blotting analysis using a speci®c antibody against p53 showed that induction of activated K-ras by Tet withdrawal resulted in a signi®cant increase in the level of p53 expression (compare lanes 1 and 2, Figure  10a ). This induction of p53 by the activated K-ras appeared to be more profound when cells growing in the presence or absence of Tet were subjected to a 24 h serum deprivation (compare lanes 3 and 4). In order to test whether the up-regulated p53 is functionally linked to the ras-mediated negative regulation of the cell cycle, we examined the eect of activated K-ras on two p53 eector proteins, the universal CDK inhibitor p21 waf1 , which plays an important role in p53-mediated cell cycle arrest in response to DNA damage (Macleod et al., 1995) , and Gadd 45, which has also been shown to inhibit entry of cells into S phase (Carrier et al., 1994) in addition to stimulation of DNA excision repair . Western blotting analysis showed that induction of activated K-ras led to a Figure 8 Eect of activated K-ras on the transcriptional activity of the cyclin A promoter. The eect of activated K-ras on the cyclin A promoter activity was measured as described in the legend for Figure 6 except that, instead of using pE2FCAT and pSVluc in the co-transfection experiments, cells were cotransfected with pAluc (which contains the cyclin A promoter driving the expression of the luciferase reporter gene) and pSV2CAT (which contains the CAT gene driven by an SV40 promoter), the results represent the means+s.e. of relative luciferase activities (after correction for transfection eciency using CAT activities) from three experiments waf1 and gadd 45. M2TK4 cells were grown to midlog phase, in the presence or absence of Tet, with or without a serum deprivation step, as described in the legend for Figure 3 . Cells were collected by trypsinization and proteins from the total cellular extract were subjected to SDS ± PAGE followed by Western blotting with a monoclonal antibody against p53 (a), or polyclonal antibodies against p21 waf1 (b) or Gadd 45 (c). Positions of these proteins are indicated by arrows. The ®gure represents one of two to four independent experiments signi®cant increase in the level of p21 expression (compare lanes 1 and 2, Figure 10b ). However, when cells (growing in the presence or absence of Tet) were subjected to a 24 h serum deprivation, p21 expression was dramatically reduced and induction of K-ras failed to upregulate p21 (lanes 3 and 4, Figure 10b ) despite that, as shown above (lanes 3 and 4 of Figure 10a ), p53 was induced under these conditions. As shown in Figure 10c , induced expression of activated K-ras led to a signi®cant increase in Gadd 45 (compare lanes 1 and 2). These data suggest that (1) Induction of activated K-ras increases expression of several negative regulators of the cell cycle such as p53 and its eectors p21 waf1 and Gadd 45; (2) regulation of p21 by activated K-ras may require the presence of certain serum factors, which is similar to the regulation of cyclins A and E by K-ras; and (3) Regulation of p21 waf1 appears to be partially p53-dependent and partially independent.
Upregulation of p53 by activated K-ras correlates with increased p53-dependent transactivation
Previous studies provided evidence that activity of p53 as a transcription factor is regulated by additional mechanisms besides transcriptional regulation of the p53 gene. These additional mechanisms include stability of the protein (Bae et al., 1995) , sequestration in the cytoplasm (Moll et al., 1995) , tetramer formation (Friedman et al., 1993) and phosphorylation (Meek and Eckhart, 1988) . Therefore, it was necessary to determine if the induced p53 protein correlated with p53-mediated transactivation. This was accomplished by transient transfection of M2TK4 cells with a plasmid containing a p53-responsive promoter which controls the expression of the CAT gene (Yamato et al., 1995) . As shown in Figure 11 , when the activated K-ras was induced by Tet withdrawal, there was a fourfold increase in overall p53 transactivation activity (as indicated by relative CAT activity after correction for transfection eciency using a separate reporter plasmid containing the luciferase gene) as compared to the result obtained from cells grown in the presence of Tet. An increase of p53 transactivation activity by activated K-ras was also observed when transfected cells growing in the presence or absence of Tet were subjected to serum deprivation (0.1% serum, 24 h) before being collected for the CAT assay.
Induction of activated K-ras up-regulates bcl-2 but has no eect on bax and bcl-x The studies described above showed that activated Kras regulates both positive and negative modulators of the cell cycle such as the tumor suppressor gene product p53 and the E2F family of transcription factors. The net result of the seemingly opposing eects of activated K-ras induction was an increase in growth rate and acceleration of the cell cycle. Overexpression of both wild type p53 and E2F induces apoptosis, at least in some cell types (Wu and Levine, 1994) . Preliminary studies in this laboratory indicated that induction of activated H-ras in MCF-7 cells renders cells more resistant to apoptotic cell death induced by treatment with DNA damaging agents such as cisplatinum (data not shown). Activated K-ras may regulate certain negative modulators of apoptosis to compensate for the positive eect of p53 and E2F on apoptosis. Therefore, the eect of activated K-ras expression on bcl-2, bax and bcl-x, three well known regulators of apoptosis (Craig, 1995) , was measured by Western blotting using speci®c antibodies against these proteins. As shown in Figure 12a , induction of activated K-ras by Tet withdrawal resulted in a signi®cant increase in the level of bcl-2 expression (compare lanes 1 and 2). Induction of bcl-2 by activated K-ras was more profound when cells growing in the presence or absence of Tet were subjected to a 24 h serum deprivation (as described above) (compare lanes 3 and 4). As shown in Figure  12b and c, no obvious dierence in the level of either bax or bcl-x expression was observed when cells were grown either in the presence or in the absence of Tet, with or without the serum deprivation step as described above. The up-regulation of bcl-2 may override the eect of increased expression of p53 and E2F on apoptosis, resulting in cells that are actually more resistant to apoptosis.
Discussion
A major objective of the current study was to examine the eect of activated K-ras on the cell cycle and to delineate the mechanism by which activated K-ras exerts this eect. A human breast carcinoma cell line MCF-7 was chosen as the model system for the current Figure 11 Eect of activated K-ras on transactivation activity of p53. The eect of activated K-ras on the p53 transactivation activity was measured as described in the legend for Figure 6 except that, instead of using pE2FCAT and pSVluc in the cotransfection experiments, cells were co-transfected with p53CONTKCAT (which contains the p53-responsive tk promoter driving the expression of the CAT reporter gene) and pSV2luc. The results represent the means+s.e. of relative CAT activities (after correction for transfection eciency using luciferase activities) from three experiments study for two major reasons: (1) it contains normal (wild type) ras genes and it has been widely used as a model (after transfection with activated ras) for studying the function of ras and (2) the cell line has been well characterized and it expresses wild type p53 and pRb (Gottardis et al., 1995) .
It was shown in this paper that activated K-ras upregulates cyclin D3 but not the other two members of the D-cyclin family (cyclins D1 and D2). To the best of our knowledge this is the ®rst report showing that members of the D-type cyclin family are dierentially regulated by activated ras. It is of interest to note that expression of cyclin D1, the only member of the D-type cyclin family considered to be an oncogene (Bates and Peters, 1995) , is not aected by activated K-ras in this particular cell type. Our results suggest that cyclin D3, identi®ed as a speci®c target for the activated K-ras in the current study, might also be classi®ed as an oncogene. These data also suggest that each member of the D-type cyclin family may be independently regulated and may play, perhaps in a tissue speci®c manner, a distinct role in cell cycle regulation. A more detailed study on the mechanism by which cyclin D3 is regulated by activated K-ras awaits the availability of the cyclin D3 promoter sequences.
Three distinct members of the E2F family of transcription factors (E2F-1, E2F-4 and E2F-5), which display preferential binding to either pRb or the pRb-like proteins p107 and p130, respectively (Weinberg, 1996) , were found to be up-regulated by activated K-ras, resulting in an overall increase in E2F transcriptional activity. In addition to up-regulating cyclins (e.g. A and E) and cyclin-associated kinase activities (e.g. CDK2 or CKD4) which would result in higher levels of`free' E2F due to phosphorylation of the pRb family proteins, it is likely that activated Kras regulates the transcription of E2Fs (i.e. the total E2F) by an unknown mechanism. Since this upregulation by activated K-ras was found in all E2F forms, activated K-ras may regulate a common transcription factor essential for transcription for all E2F genes.
Several studies indicate that stabilization of the p53 protein might be a major mechanism for p53 accumulation in response to DNA damage (Canman et al., 1994; Di Leonardo et al., 1994) . Although most studies show that MCF-7 cells contain wild type p53 (Takahashi et al., 1992; Balcer-Kubiczek et al., 1995) , there have been some questions as to the functional status of the p53 tumor suppressor gene product present in MCF-7 cells (Casey et al., 1991) , the model cell line used in this study. Our data, obtained by use of a p53-responsive promoter construct suggests that the p53 protein up-regulated by activated K-ras in M2TK4 cells is transcriptionally active. In addition, activated K-ras induced both p21 waf1 and Gadd 45, two well characterized p53 eectors whose expression is known to be controlled by p53 at the transcriptional level (Carrier et al., 1994; Macleod et al., 1995) . Therefore MCF-7 cells used in this study most likely contain wild-type p53. Studies in this laboratory (Fan and Bertino, 1997) and elsewhere (Hiebert et al., 1995) show that E2F-1 positively regulates p53 expression. As activated K-ras up-regulated three major forms of E2F, it is very likely that activated K-ras up-regulates p53 via a transcriptional mechanism, most probably via up-regulated E2F activity. A previous study showed that MCF-7 cells, despite containing wild type p53, lack wild type p53 activity due to nuclear exclusion of p53. This suggests that activated K-ras may also regulate the activity of p53 by mechanisms other than gene regulation, such as post-translational modi®cation.
The observation that p27 Kip1 was down-regulated and p21
Waf1 was up-regulated by activated K-ras represents the ®rst instance in which two CDK inhibitors are dierentially regulated. Since expression of either p27 Kip1 or p21
Waf1 can result in cell cycle arrest (Toyoshima and Hunter, 1994; Wu et al., 1996) , their dierent regulation by activated K-ras cannot be perceived as a simple cell cycle eect. The same logic would be applicable to p53 and Gadd 45. Exactly how these CDK inhibitors are regulated by activated K-ras remains to be investigated.
Since both p53 and Gadd 45 have been implicated in DNA repair Gotz and Montenarh, 1996) and both of these molecules were up-regulated by activated K-ras, it is conceivable that cells containing activated K-ras would have a higher capacity for DNA repair. This would provide an explanation for activated ras mediated drug and radiation resistance Eect of activated K-ras on expression of the bcl-2 family members. M2TK4 cells were grown to mid-log phase, in the presence or absence of Tet, with or without a serum deprivation step, as described in the legend for Figure 3 . Cells were collected by trypsinization and proteins from the total cellular extract were subjected to SDS ± PAGE followed by Western blotting with speci®c polyclonal antibodies against bcl-2 (a), bax (b) or bcl-x (c). Positions of these proteins are indicated by arrows. The ®gure represents one of two to four independent experiments from previous studies in this laboratory (Fan et al., 1997) and elsewhere (Levy et al., 1994; Sklar, 1988) . Up-regulation of bcl-2, but not bax or bcl-x, important regulators of apoptosis, by activated K-ras may explain why cells containing activated ras are generally more resistant to drug-or radiation-induced apoptosis, despite the up-regulation of both p53 and E2F by activated K-ras, shown previously to cooperate to induce apoptosis in Rat ®broblast cells (Wu and Levine, 1994) . Up-regulation of bcl-2 by K-ras also suggests that activated K-ras can overcome the inhibitory eect of p53 on bcl-2 expression . Although ras activation is generally believed to have a positive eect on cell cycle progression, several reports indicate that activated ras can induce cell cycle arrest in certain cell types (Pan et al., 1994; Hirakawa and Ruley, 1988) . Data presented in this paper provide strong evidence that activated K-ras exerts its eect on the cell cycle by modulating the expression of a diverse spectrum of cell cycle regulators such as the tumor suppressor protein p53 and the E2F family of transcription factors. The eect of activated ras on the cell cycle is characterized by two opposing functions: one is the negative regulatory function which is ful®lled by up-regulated p53 (accompanied by increased expression of p21 waf1 and Gadd45) and the other is the positive regulatory function accomplished by increased expression of E2Fs and cyclins (A, E, and D3) and decreased expression of p27 Kip1 . The net eect of activated K-ras on the cell cycle will be determined by a balance of these two opposing functions. When the negative cell cycle regulatory function of activated K-ras predominates over the positive eect, induction of activated K-ras may lead to slower cell growth or cell cycle arrest, and vice versa. Other factors such as the environment (such as growth factors) and cell types may also aect whether or not activated ras will have a positive or a negative eect on the cell cycle. Some investigators suggested that expression of activated ras at a level above certain threshold can result in growth arrest (Ricketts and Levinson, 1988) .
Induction of wild type p53 activity (and subsequent induction of p21 waf1 and Gadd 45) may be a major component of the negative cell cycle regulatory function of activated K-ras. This notion is supported by two previous studies showing that both dominant negative mutants of p53 (Hicks et al., 1991) and the SV40 large T antigen (which binds to and inactivates p53) (Hirakawa and Ruley, 1988) were able to release ras-induced cell cycle arrest in a rat ®broblast cell line (REF52). The expected selective inhibition by mdm2 (believed to be an inhibitor of p53 (Finlay, 1993; ) of the negative regulatory function would explain the ®nding by Finlay (1993) that mdm2 together with activated ras can transform cells. Data presented in this paper also suggest that ras activation, as shown in this study, combined with ®ndings from others regarding p53 loss, could lead to accelerated growth rates.
For chemotherapeutic purposes, targeting (and inhibition of) the positive cell cycle regulatory function of activated ras while leaving the other (negative regulatory) function intact may be a more eective and speci®c way to inhibit ras-mediated tumorigenesis than targeting ras directly (Abrams et al., 1996; Blume, 1993) , especially if the tumor contains functional p53. Targeting ras directly may be complicated by the fact that ras is central to many cellular processes. It is reasonable to assume that in tumors containing both mutant p53 and activated ras, gene therapy with wild type p53 may not be an eective approach since the eects of p53 (which is inducible by ras) on the cell cycle and apoptosis may be oset by other eects of activated ras such as upregulation of E2F and bcl-2.
Materials and methods
Chemicals and reagents
Tetracycline, bromodeoxyuridine (BrdU), propidium iodide, histone H1, bovine serum albumin (BSA), and acetyl CoA were obtained from Sigma. Geneticin (G418) 
Antibodies
Antibodies against K-ras, cyclin D1, cyclin D3, cyclin A, E2F-1, E2F-4, E2F-5, bcl-2, bax, bcl-x, p53, p21, p27, Gadd 45 and anti-cyclin A-agarose conjugates were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-cyclin D2 antibody was obtained from NeoMarkers (Fremont, CA). Fluorescein isothiocyanate (FITC)-conjugated Anti-BrdU antibody was purchased from Becton Dickinson Immunocytometry Systems (Mountain View, CA). Polyclonal antibodies against human dihydrofolate reductase (DHFR) and thymidylate synthase (TS) were generous gifts from Dr Bruce Dolnick and Dr Frank Maley, respectively.
Cell line
The MCF-7 breast adenocarcinoma cell line was obtained from American Type Culture Collection and was maintained as monolayer cultures at 378C in a 5% CO 2 /95% air incubator in RPMI 1640 medium supplemented with 10% fetal bovine serum.
Plasmids
The tetracycline inducible system plasmids pUHD10-3 and pUHD15-1 (Gossen and Bujard, 1992) were generous gifts from Dr Herman Bujard (Heidelberg, Germany) . pAluc, which contains the cyclin A promoter linked to the ®re¯y luciferase cDNA (Henglein et al., 1994) , was provided by Dr Berthold Henglein (Paris, France). pE2FCAT which contains the E2F-responsive promoter linked to the chloramphenicol transferase (CAT) cDNA (Buck et al., 1995) was provided by Dr ReneÂ Bernards (Amsterdam, The Netherlands). p53CONTKCAT which contains the p53-responsive tk promoter linked to the CAT cDNA (Yamato et al., 1995) was obtained from Dr Nobuo Tsuchida (Tokyo, Japan). All plasmid DNAs were prepared from E. coli strain DH5a and puri®ed by ion exchange chromatography using the Plasmid Midi Kit from Qiagen (Chatsworth, CA).
Construction of an inducible vector system for an activated human K-ras
The tetracycline (Tet) responsive system (Gossen and Bujard, 1992) , which is composed of two plasmids (pUHD10-3 and pUHD15-1), was used to construct the inducible vectors for controlled expression of activated Kras. First, pUHD15-1 was modi®ed to contain the selectable marker neo. This was accomplished by cloning the 1.1 kb tTA fragment from pUHD15-1 into the multiple cloning site of the plasmid pcDNA3 (Invitrogene, CA); the resulting plasmid is designated as pcdtTA. Then pUHD10-3 was modi®ed to contain the cDNA sequences for human K-ras with a Gly 12 ?Val 12 mutation (obtained from ATCC). The resulting plasmid is designated as pUHDkras2.
Cloning of MCF-7 cells
MCF-7 cells were cloned using the dilution method with a 96-well plate. Four dierent single clones were obtained and expanded into cell lines. One clone (#2) was used for transfection studies. DNA sequencing analysis showed that cells from all of these clones of MCF-7 contain a normal K-ras gene.
Stable transfection of the inducible activated K-ras construct into MCF-7 cells
The transfection of a single clone of MCF-7 cells with the Tet responsive system for the activated K-ras was accomplished by use of a two plasmid co-transfection protocol and a lipofection procedure (Stamatatos et al., 1988) . Cells were allowed to grow to ca. 50% con¯uency in a 100 mm petri dish in a medium containing 1 mg/ml Tet. A total of 20 mg of the two plasmids (pUHDkras2 and pcdtTA) at a molar ratio of 10 : 5 were mixed with 70 ml of the lipofectant DOTAP in a total of 0.5 ml HBS (20 mM HEPES, pH 7.4 and 150 mM NaCl) and incubated at room temperature for 10 min. Fourteen ml of fresh growth medium containing Tet at 1 mg/ml were added and, after removal of old medium from cells, the mixture was then added to cells and incubation continued for 24 h. Cells were split 1 : 5 and grown in a medium containing 1 mg/ml Tet. G418 selection began 24 h later at a concentration just high enough to kill 100% of the parental (untransfected) cells (800 mg/ml). About 2 ± 5 weeks later, colonies were picked by the cloning cylinder technique and expanded into cell lines. Incorporation into these transfected cell lines of the inserted inducible activated K-ras cDNA was veri®ed by use of PCR ampli®cation using a CMV promoterspeci®c primer and a K-ras cDNA-speci®c primer.
Western blot analysis
MCF-7-K-ras cells were grown to mid-log phase in the presence of 1 mg/ml of Tet. After being washed extensively to remove extraneous Tet, the cells were collected by trypsinization and split equally into two culture¯asks containing or lacking 1 mg/ml Tet, respectively. After 24 h incubation, the medium in each¯ask was changed with fresh media containing or lacking 1 mg/ml Tet. After an additional 48 h incubation, cells were harvested by trypsinization, washed with phosphate buered saline (PBS), and solubilized with a buer (50 mM NaCl, 20 mM Tris-HCl, pH 7.4) containing 2% (v/v) Nonidet P-40 (NP-40), 0.5% (w/v) sodium deoxycholate and 0.2% (w/v) sodium dodecyl sulfate (SDS), plus a mixture of protease inhibitors (20 mg/ml leupeptin, 30 mg/ml aprotinin, 10 mg/ ml pepstatin A, 20 mg/ml soybean trypsin inhibitor, 1 mM PMSF and 1 mM sodium orthovanadate). The extract was centrifuged at 60 000 g for 30 min to remove any insoluble cellular debris and the protein concentration was determined by the Bicinchoninic Acid (BCA) assay according to the manufacturer's instructions (Pierce). The cell extract (containing 150 mg of total protein) was mixed with equal volume of 26SDS sample buer (20% (v/v) glycerol, 125 mM Tris-HCl, pH 6.8, 1% (v/v) b-mercaptomethanol and 0.05% (w/v) bromophenol blue) and loaded onto a 12.5% polyacrylamide gel containing SDS (Laemmli, 1970) . After electrophoresis, the proteins were electrotransferred to a nitrocellulose membrane and the latter was probed with an antibody (either a mouse monoclonal or a rabbit polyclonal), followed by a second antibody (either anti-mouse IgG or anti rabbit IgG) conjugated with peroxidase. The protein of interest was then visualized by treatment of the membrane with the Enhanced Chemiluminescence (ECL) reagents (Amersham) followed by exposure to a X-ray ®lm.
Cell cycle analysis
Cells (5710610 6 ) growing exponentially at ca. 70% con¯uency in the presence or absence of Tet (1 mg/ml) were pulse-chase labeled with 10 mM BrdU for 3 h at 378C in a CO 2 incubator. Cells were washed twice with PBS/BSA (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 and 1% (w/v) BSA) and detached from the¯ask by trypsinization. After centrifugation at 500 g for 15 min at 48C and resuspension in 100 ml of normal saline (0.9% (w/v) NaCl) on ice, the cells were slowly added drop-wise to 5 ml pre-chilled (7208C) 70% ethanol while maintaining a vortex. After incubation on ice for 30 min, the cell pellet was obtained by centrifugation, washed once with cold PBS, and resuspended by vortexing in 1 ml of 2N HCl containing 0.5% (v/v) Triton X-100. After another incubation for 30 min at room temperature, the cells were centrifuged at 500 g for 10 min and the pellet was resuspended in 1 ml of 0.1 M Na 2 B 4 O 7 (pH 8.5). Cells (1610 6 ) were centrifuged and the pellet was resuspended in 50 ml PBS containing 0.5% (v/v) Tween-20 and 1% (w/v) BSA. After addition of 20 ml of FITC conjugated antiBrdU antibody and incubation for 30 min at room temperature, the cells were pelleted by centrifugation and resuspended in 1 ml PBS containing 5 mg/ml of propidium iodide (PI). The cell suspension was stored at 48C overnight before analysis with a Becton Dickinson FACS ow cytometer. BrdU staining (FITC¯uorescence) was plotted as a function of DNA content (PI¯uorescence). Cells which were not labeled with BrdU but stained with FITC-BrdU antibody served as the control for background or non-speci®c anti-BrdU¯uorescence so that percent of BrdU-positive (i.e. S phase) cells could be calculated.
Histone H1 kinase assays
The following was based on the procedures of Bortner and Rosenberg (1995) , with modi®cations. Cells (1610 7 ) growing exponentially at ca. 70% con¯uency in the presence or absence of Tet (1 mg/ml) were collected and the cell pellet was resuspended in 0.2 ml lysis buer (100 mM Tris-HCl (pH 7.5) containing 300 mM NaCl, 2% (v/v) NP-40, 0.5% sodium deoxycholate, 0.2% (w/v) SDS, 20 mg/ml leupeptin, 30 mg/ml aprotinin, 10 mg/ml pepstatin A, 20 mg/ml soybean trypsin inhibitor, 1 mM PMSF and 1 mM sodium orthovanadate). After incubation for 30 min on ice, the cell lysate was centrifuged at 15 000 r.p.m. (Eppendorf) for 15 min at 48C. The protein concentration of the supernatant was determined by the BCA assay as described above. The cell extract containing 200 mg of protein was treated with 50 ml of protein A/protein G plus agarose on a rotator for 30 min at 48C and the agarose beads were pelleted by centrifugation for 5 min at 1500 g (Eppendorf). The supernatant was then mixed with 16 ml of anti-cyclin A-agarose or with 3 mg of anti-cyclin D3 antibody plus 50 ml protein A/protein G plus-agarose. The mixture was rotated at 48C for 16 h and the agarose beads were recovered by centrifugation, washed 46 with lysis buer, and once with kinase buer (50 mM HEPES (pH 7.5) containing 150 mM NaCl, 10 mM MgCl 2 , 1 mM dithiothreitol (DTT) and 2 mM ethylene glycosyl-bis(baminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA)), and resuspended in 20 ml (for cyclin A) or 30 ml (for cyclin D3) of kinase buer containing 100 mg/ml Histone H1, 10 mM ATP and 300 mCi/ml [g-32 P]ATP. The kinase reaction was allowed to proceed for 1 h at 308C and was stopped by addition of equal volume of 26SDS sample buer. After being boiled for 3 min, the mixture was loaded onto a 12.5% polyacrylamide gel containing SDS and electrophoresis was performed at 10 mA at 48C until the dye front reached 2 cm from the bottom of the gel. The gel was then dried and exposed to an X-ray ®lm.
Transient transfections
MCF-7-K-ras cells were grown to mid-log phase in the presence of 1 mg/ml of Tet. After being washed extensively to remove extraneous Tet, the cells were collected by trypsinization and seeded at 1610 6 cells per plate into two separate sets of 100 cm culture dishes both of which contain 10 ml of RPMI 1640 medium supplemented with 10% serum; one group had 1 mg/ml of Tet added and the other had no Tet. After 24 h incubation at 378C, the medium in each set of dishes was changed with fresh respective media containing or lacking 1 mg/ml Tet and incubation continued for 5 h. Ten mg of total plasmid DNA consisting of the reporter plasmid and control plasmid were mixed with 0.5 ml serum-free RPMI 1640 medium and the resulting DNA mixture was incubated for 1 h at room temperature. Fifty mg of the lipofectant DOTAP/DOPE (1 : 1) were mixed with 0.5 ml serum-free RPMI 1640 medium and the resulting liposome mixture was incubated for 1 h at room temperature. The DNA mixture and the liposome mixture were combined and incubated for another 30 min at room temperature. The DNA/liposome mixture, after being diluted by addition of 6.5 ml of RPMI-1640 medium supplemented with 0.1% serum, with or without 1 mg/ml of Tet, was added to cells in the culture plates whose medium had been removed. After incubation at 378C for 5 h, 7.5 ml of RPMI 1640 medium supplemented with 20% serum, with or without Tet, was added to each dish and incubation was continued at 378C for 16 h. Medium from each dish was replaced with fresh medium supplemented with 10% serum, with or without 1 mg/ml of Tet, respectively and incubation was continued further at 378C 48 h. After being washed twice with PBS, the transfected cells from each dish were recovered by use of 0.6 ml of the Reporter Lysis Buer (Promega) and by scraping with a rubber policeman. The cell lysate was transferred to an Eppendorf tube and centrifuged to pellet large cell debris. The supernatant was stored at 7708C or used immediately for CAT and luciferase assays.
CAT and luciferase activity assays
The CAT activity of the cell lysate prepared from the transfected cells (see above) was measured by use of 14 Clabeled acetyl Coenzyme A and chloramphenicol as substrates and a radio diusion procedure according to manufacturer's instructions. Brie¯y, 50 ml of cell lysate was mixed with 0.2 ml 1.25 mM Chloramphenicol in 100 mM Tris buer (pH 7.8) in a 7 ml glass scintillation vial. The reaction was initiated by adding 0.1 mCi [
14 C] Acetyl CoA and 22.5 ml 1 mM cold acetyl CoA. Five ml of Econo¯uor-2 was gently overlaid and the vials were incubated at room temperature. At timed intervals, the vials were counted using a Beckman Liquid Scintillation Counter. Relative CAT activity was calculated by comparison of the increase in counts over time. The luciferase activity was measured by use of the Luciferase Assay Reagent (Promega) according to the manufacturer's instructions. Brie¯y, 20 ml of cell lysate and 100 ml of the Luciferase Assay Reagent, both of which were pre-warmed to room temperature, were mixed and the relative light units produced for a period of 20 s were measured immediately on a luminometer (Monolight 2010, Analytical Luminescence Laboratory).
